The fair value estimate for Microbot Medical has been reduced from US$6.33 to about US$5.38, a move that reflects a roughly 15% cut to the price target. Recent analyst commentary ties this shift to a more cautious view on how quickly hospitals may adopt the Liberty system and convert early interest into recurring orders. As you read on, you will see how these updated assumptions shape the evolving Microbot Medical story and what to watch next. Stay updated as the Fair Value for Microbot...
ELMNT IR also became the first account on the West Coast, marking a geographic expansion which aligns with the Company’s Full Market Release strategy. The Company believes the OBLs represent a rapidly growing healthcare segment and opportunity as many endovascular procedures are being done outside traditional hospital settings and Ambulatory Surgery Centers. HINGHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY
Detailed price information for Microbot Medical Inc (MBOT-Q) from The Globe and Mail including charting and trades.
Detailed price information for Microbot Medical Inc (MBOT-Q) from The Globe and Mail including charting and trades.
This post contains sponsored content and was created in collaboration with a third-party partner. Benzinga is a publisher and does not provide personalized investment advice or act as a broker or dealer. This content is
Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.